BR112012027062A2 - composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica - Google Patents
composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêuticaInfo
- Publication number
- BR112012027062A2 BR112012027062A2 BR112012027062A BR112012027062A BR112012027062A2 BR 112012027062 A2 BR112012027062 A2 BR 112012027062A2 BR 112012027062 A BR112012027062 A BR 112012027062A BR 112012027062 A BR112012027062 A BR 112012027062A BR 112012027062 A2 BR112012027062 A2 BR 112012027062A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- conditions
- preventing
- preparation
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/44—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica. derivados de tranilcipromina úteis como agentes terapêuticos, particularmente para a prevenção e/ou tratamento de doenças e condições associadas à atividade de histonas demetilases lsd1 e lsd2, tais como as doenças caracterizadas por desregulação da transcrição de gene, diferenciação e proliferação de célula, por exemplo, tumores, infecções virais, são descritos aqui. esses compostos pertencem à fórmula estrutural (i) em que a e r~ 3~ são como definido no relatório descritivo. a invenção também se refere à preparação desses compostos, bem como a composições que os contêm e a seu uso terapêutico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32595210P | 2010-04-20 | 2010-04-20 | |
US61/325,952 | 2010-04-20 | ||
PCT/EP2011/055990 WO2011131576A1 (en) | 2010-04-20 | 2011-04-15 | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112012027062A2 true BR112012027062A2 (pt) | 2017-03-14 |
BR112012027062B1 BR112012027062B1 (pt) | 2021-04-20 |
BR112012027062B8 BR112012027062B8 (pt) | 2021-05-25 |
Family
ID=43929076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012027062A BR112012027062B8 (pt) | 2010-04-20 | 2011-04-15 | composto, processo para a preparação de um composto e usos do mesmo |
Country Status (12)
Country | Link |
---|---|
US (1) | US8765820B2 (pt) |
EP (1) | EP2560949B1 (pt) |
JP (1) | JP5934184B2 (pt) |
CN (1) | CN102985402B (pt) |
AU (1) | AU2011244478B2 (pt) |
BR (1) | BR112012027062B8 (pt) |
CA (1) | CA2797011C (pt) |
EA (1) | EA022459B1 (pt) |
ES (1) | ES2564352T3 (pt) |
PL (1) | PL2560949T3 (pt) |
WO (1) | WO2011131576A1 (pt) |
ZA (1) | ZA201207856B (pt) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
KR101794020B1 (ko) | 2010-04-19 | 2017-11-06 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
RU2611437C2 (ru) | 2010-07-29 | 2017-02-22 | Оризон Дженомикс С.А. | Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине |
WO2012045883A1 (en) * | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
WO2012107499A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
EP2743256B1 (en) * | 2011-08-09 | 2018-06-27 | Takeda Pharmaceutical Company Limited | Cyclopropaneamine compound |
CN107417549A (zh) | 2011-10-20 | 2017-12-01 | 奥莱松基因组股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙基胺化合物 |
BR112014009306B1 (pt) * | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
CA2887598A1 (en) | 2012-10-12 | 2014-04-17 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
CA2920257C (en) | 2013-08-06 | 2023-02-21 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
MX2016010395A (es) | 2014-02-13 | 2017-02-28 | Incyte Corp | Ciclopropilamina como inhibidor de la desmetilasa 1 especifica de lisinas (lsd1). |
EA034197B1 (ru) | 2014-04-11 | 2020-01-16 | Такеда Фармасьютикал Компани Лимитед | Циклопропанаминовое соединение и его применение |
AU2015265820C1 (en) * | 2014-05-30 | 2020-01-16 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
EP2949648A1 (en) | 2014-05-30 | 2015-12-02 | IEO - Istituto Europeo di Oncologia Srl | Cyclopropylamine derivatives as histone demethylase inhibitors |
KR102450671B1 (ko) * | 2014-07-03 | 2022-10-04 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 저해제 |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
KR102476459B1 (ko) | 2014-09-05 | 2022-12-09 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
ES2973286T3 (es) * | 2014-11-26 | 2024-06-19 | St Europeo Di Oncologia S R L | Modelos de trastornos del desarrollo neurológico basados en la reprogramación y usos de los mismos |
JP6636031B2 (ja) * | 2015-01-30 | 2020-01-29 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
AU2016219041B2 (en) | 2015-02-12 | 2021-03-11 | Imago Biosciences, Inc. | KDM1A inhibitors for the treatment of disease |
CR20170500A (es) | 2015-04-03 | 2018-02-02 | Incyte Corp | Compuestos heterocíclicos como inhibidores de lsd1 |
EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
MX2017015922A (es) | 2015-06-12 | 2018-12-11 | Oryzon Genomics Sa | Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos. |
WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
TWI765860B (zh) | 2015-08-12 | 2022-06-01 | 美商英塞特公司 | Lsd1抑制劑之鹽 |
TWI679195B (zh) | 2015-11-27 | 2019-12-11 | 日商大鵬藥品工業股份有限公司 | 新穎聯苯化合物或其鹽 |
WO2017097865A1 (en) * | 2015-12-07 | 2017-06-15 | Istituto Europeo Di Oncologia | Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor |
IL261721B (en) | 2016-03-15 | 2022-07-01 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
SG11201807972YA (en) | 2016-03-15 | 2018-10-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
EP3430015A1 (en) | 2016-03-16 | 2019-01-23 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
SG10202010414QA (en) | 2016-04-22 | 2020-11-27 | Incyte Corp | Formulations of an lsd1 inhibitor |
EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
PL3307267T3 (pl) | 2016-06-10 | 2019-10-31 | Oryzon Genomics Sa | Leczenie stwardnienia rozsianego |
US11390590B2 (en) | 2016-08-16 | 2022-07-19 | Imago Biosciences, Inc. | Methods and processes for the preparation of KDM1A inhibitors |
EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
US11918580B2 (en) | 2017-04-26 | 2024-03-05 | Istituto Europeo Di Oncologia S.R.L. | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer |
MA50466A (fr) | 2017-05-26 | 2020-09-02 | Taiho Pharmaceutical Co Ltd | Nouveau composé de biphényle ou sel de celui-ci |
PT3632443T (pt) * | 2017-05-26 | 2023-08-31 | Taiho Pharmaceutical Co Ltd | Potenciador de efeito antitumoral que utiliza um composto de bifenilo |
SG11202000077RA (en) | 2017-08-03 | 2020-02-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
WO2019034774A1 (en) | 2017-08-18 | 2019-02-21 | Istituto Europeo Di Oncologia (Ieo) S.R.L. | INDOLE DERIVATIVES AS HISTONE DEM ETHYLASE INHIBITORS |
WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
KR102684364B1 (ko) | 2018-05-11 | 2024-07-11 | 이마고 바이오사이언시즈 인코포레이티드 | 질환의 치료를 위한 kdm1a 저해제 |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
CN112672994B (zh) * | 2018-09-13 | 2022-09-13 | 南昌弘益药业有限公司 | 作为lsd1抑制剂的杂螺环类化合物及其应用 |
CA3130638A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
JP7535797B2 (ja) | 2019-03-20 | 2024-08-19 | オリソン ヘノミクス,ソシエダ アノニマ | 化合物バフィデムスタット(vafidemstat)などkdm1a阻害剤を使用した注意欠陥多動性障害の処置方法 |
CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
IT202000007873A1 (it) | 2020-04-14 | 2021-10-14 | St Europeo Di Oncologia S R L | Molecole per uso nel trattamento delle infezioni virali |
CN111454252B (zh) * | 2020-05-13 | 2021-06-11 | 郑州大学 | 含芳环/芳杂环-三氮唑-亚甲基-tcp衍生物及其制备方法和应用 |
CA3184924A1 (en) * | 2020-07-04 | 2022-01-13 | Jin Li | Immunomodulator |
KR20220027555A (ko) | 2020-08-27 | 2022-03-08 | 재단법인대구경북과학기술원 | 트라닐시프로민을 유효성분으로 포함하는 신경염증성 질환의 예방 또는 치료용 약학적 조성물 |
EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
WO2022058405A2 (en) | 2020-09-16 | 2022-03-24 | Ifom - Istituto Firc Di Oncologia Molecolare | Histone deacetylase inhibitors and uses thereof |
CN113750095B (zh) * | 2021-03-10 | 2023-07-04 | 中国医学科学院医药生物技术研究所 | 含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用 |
JP2024513260A (ja) | 2021-04-08 | 2024-03-22 | オリゾン ジェノミックス ソシエダッド アノニマ | 骨髄癌処置のためのlsd1阻害剤の組み合わせ |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9311282D0 (en) * | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | New compositions of matter |
WO1997036858A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Cyclopropyl alkanoic acid derivatives |
US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
WO2005007614A1 (en) * | 2003-07-03 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 | Monoamine oxidase inhibitors |
WO2005007111A2 (en) * | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
TW200530246A (en) * | 2003-12-19 | 2005-09-16 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
EP1693062A3 (en) | 2005-02-18 | 2007-12-12 | Universitätsklinikum Freiburg | Androgen receptor-dependent gene expression control |
GB0705656D0 (en) * | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
WO2010011845A2 (en) * | 2008-07-24 | 2010-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of preventing or treating viral infection or reactivation after latency in a host using inhibitors of the lsd1 protein |
WO2010043721A1 (en) * | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010084160A1 (en) * | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
-
2011
- 2011-04-15 EP EP11716208.1A patent/EP2560949B1/en active Active
- 2011-04-15 WO PCT/EP2011/055990 patent/WO2011131576A1/en active Application Filing
- 2011-04-15 CN CN201180019945.2A patent/CN102985402B/zh active Active
- 2011-04-15 CA CA2797011A patent/CA2797011C/en active Active
- 2011-04-15 ES ES11716208.1T patent/ES2564352T3/es active Active
- 2011-04-15 JP JP2013505423A patent/JP5934184B2/ja active Active
- 2011-04-15 US US13/641,715 patent/US8765820B2/en active Active
- 2011-04-15 AU AU2011244478A patent/AU2011244478B2/en active Active
- 2011-04-15 PL PL11716208T patent/PL2560949T3/pl unknown
- 2011-04-15 BR BR112012027062A patent/BR112012027062B8/pt active IP Right Grant
- 2011-04-15 EA EA201291073A patent/EA022459B1/ru not_active IP Right Cessation
-
2012
- 2012-10-18 ZA ZA2012/07856A patent/ZA201207856B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2797011C (en) | 2018-10-02 |
CA2797011A1 (en) | 2011-10-27 |
EP2560949B1 (en) | 2015-12-02 |
US20130035377A1 (en) | 2013-02-07 |
US8765820B2 (en) | 2014-07-01 |
JP5934184B2 (ja) | 2016-06-15 |
ZA201207856B (en) | 2013-06-29 |
AU2011244478B2 (en) | 2014-07-17 |
AU2011244478A1 (en) | 2012-11-01 |
WO2011131576A1 (en) | 2011-10-27 |
CN102985402B (zh) | 2015-04-29 |
EA201291073A1 (ru) | 2013-10-30 |
JP2013525318A (ja) | 2013-06-20 |
ES2564352T3 (es) | 2016-03-22 |
PL2560949T3 (pl) | 2017-01-31 |
BR112012027062B8 (pt) | 2021-05-25 |
EP2560949A1 (en) | 2013-02-27 |
BR112012027062B1 (pt) | 2021-04-20 |
EA022459B1 (ru) | 2016-01-29 |
CN102985402A (zh) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012027062A2 (pt) | composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica | |
BR112012014899A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
BR112013021537A2 (pt) | derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase | |
BR112014026383A2 (pt) | derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1 | |
BRPI0911476A2 (pt) | compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos | |
BR112014010576A8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
BR112015029972A2 (pt) | composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto | |
BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
BR112014027181A2 (pt) | derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1 | |
BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
BR112015012454A8 (pt) | compostos inibidores de atr quinase, seu uso, composição farmacêutica compreendendo os mesmos, seus intermediários e método de preparação | |
BRPI0913580B8 (pt) | compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos | |
UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
BR122013028005B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos | |
BR112013000107A2 (pt) | aminopirazoloquinazolinas | |
BR112013005622A2 (pt) | heteroaril metil amidas | |
BR112014000713A2 (pt) | derivados de indol substituído como moduladores de gama secretase | |
BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: UNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2011 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |